These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 16752306)
21. Aberrant histone acetylation and methylation levels in woman with endometriosis. Xiaomeng X; Ming Z; Jiezhi M; Xiaoling F Arch Gynecol Obstet; 2013 Mar; 287(3):487-94. PubMed ID: 23080547 [TBL] [Abstract][Full Text] [Related]
22. Functional role of G9a-induced histone methylation in small heterodimer partner-mediated transcriptional repression. Boulias K; Talianidis I Nucleic Acids Res; 2004; 32(20):6096-103. PubMed ID: 15550569 [TBL] [Abstract][Full Text] [Related]
23. Aurora kinase inhibitors as anti-cancer therapy. Lok W; Klein RQ; Saif MW Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367 [TBL] [Abstract][Full Text] [Related]
24. Specificity of protein lysine methyltransferases and methods for detection of lysine methylation of non-histone proteins. Rathert P; Dhayalan A; Ma H; Jeltsch A Mol Biosyst; 2008 Dec; 4(12):1186-90. PubMed ID: 19396382 [TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase inhibitors. Marks PA; Richon VM; Miller T; Kelly WK Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890 [TBL] [Abstract][Full Text] [Related]
27. [A new target of cancer therapy: advances in the study of histone deacetylase]. Liu AL; Long J; Wang N; Du GH Yao Xue Xue Bao; 2005 Jul; 40(7):585-90. PubMed ID: 16196262 [No Abstract] [Full Text] [Related]
28. Histone deacetylases and cancer: causes and therapies. Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574 [TBL] [Abstract][Full Text] [Related]
29. Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells. Imesch P; Fink D; Fedier A Fertil Steril; 2010 Dec; 94(7):2838-42. PubMed ID: 20605144 [TBL] [Abstract][Full Text] [Related]
34. Regulation and function of H3K9 methylation. Shinkai Y Subcell Biochem; 2007; 41():337-50. PubMed ID: 17484135 [TBL] [Abstract][Full Text] [Related]
35. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Hodawadekar SC; Marmorstein R Oncogene; 2007 Aug; 26(37):5528-40. PubMed ID: 17694092 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of histone deacetylase 3 produces mitotic defects independent of alterations in histone H3 lysine 9 acetylation and methylation. Warrener R; Chia K; Warren WD; Brooks K; Gabrielli B Mol Pharmacol; 2010 Sep; 78(3):384-93. PubMed ID: 20562223 [TBL] [Abstract][Full Text] [Related]
37. Cancer treatment of the future: inhibitors of histone methyltransferases. Spannhoff A; Sippl W; Jung M Int J Biochem Cell Biol; 2009 Jan; 41(1):4-11. PubMed ID: 18773966 [TBL] [Abstract][Full Text] [Related]
38. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Bush EW; McKinsey TA Circ Res; 2010 Feb; 106(2):272-84. PubMed ID: 20133912 [TBL] [Abstract][Full Text] [Related]
39. Epigenetic cancer therapy: Proof of concept and remaining challenges. Mund C; Lyko F Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865 [TBL] [Abstract][Full Text] [Related]
40. Regulation of protein turnover by acetyltransferases and deacetylases. Sadoul K; Boyault C; Pabion M; Khochbin S Biochimie; 2008 Feb; 90(2):306-12. PubMed ID: 17681659 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]